| Name | Title | Contact Details |
|---|
Since its beginning in 1902` Cedars-Sinai has evolved to meet the healthcare needs of one of the most diverse regions in the nation` continually setting new standards for quality and innovation in patient care` research` teaching and community service. Today` Cedars-Sinai is widely known for its national leadership in transforming healthcare for the benefit of patients. Cedars-Sinai receives consistent recognition for our excellence. Our awards include; being named one of America`s Best Hospitals by U.S. News & World Report` receiving the National Research Corporation`s Consumer Choice Award 19 years in a row for providing the highest-quality medical care in Los Angeles` achieving the longest-running Magnet designation for nursing excellence in California` and being recognized as The Advisory Board Company`s 2017 Workplace of the Year` an award Cedars-Sinai has won three years in a row. This annual award recognizes hospitals and health systems nationwide that have outstanding levels of employee engagement. Cedars-Sinai is a leader in the clinical care and research of heart disease` cancer and brain disorders` among other areas. Pioneering research achievements include using cardiac stem cells to repair damaged hearts` developing minimally invasive surgical techniques and discovering new types of drugs to target cancer more precisely. Cedars-Sinai also impacts the future of healthcare through education programs that encompass everything from highly competitive medical residency and fellowship programs to a biomedical science and translational medicine PhD program` advanced training for nurses and educational opportunities for allied health professionals. Most notably` Cedars-Sinai demonstrates a longstanding commitment to strengthening the Los Angeles community through wide-ranging programs that improve the health of its most vulnerable residents.
Evergreen Medical Technologies is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Glengariff Health Care Ctr is a Glen Cove, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Partnering with more than 1,800 physicians at more than 235 outpatient surgery centers across the United States, AmSurg is the nationally recognized leader in the development, management and operation of outpatient surgery centers. AmSurg surgery centers provide high quality, low cost surgical services with superior patient satisfaction. We believe in empowering our physician partners to achieve their professional and personal goals by providing innovative operational, clinical and strategic services.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.